General Information
CROATIAN PHARMACEUTICAL SOCIETY
and
SLOVENIAN PHARMACEUTICAL SOCIETY
Acta Pharmaceutica is a single-blind, peer-reviewed journal (at least two independent referees after the desk pre-review). It is a journal with fully open access (“gold” OA) and “early bird” platform. To reach the highest standards in publication ethics all the parties (authors, editors, reviewers) are required to behave responsibly and ethically. This implies submittance by authors on an exclusive basis, of only their own and new data; novelty and originality are prioritized. Submission of materials generated by AI is discouraged. Manuscripts should be submitted exclusively to the editorial office of Acta Pharmaceutica. Submission of materials generated by AI is discouraged. Neither is allowed to submit paper-mills produced materials. Only submissions received from authentic institutional e-mail addresses will be further processed. Also, secure handling of confidential data by reviewers and editors is a must.
Acta Pharmaceutica has a printing run of 250 copies and it is partly supported by the Ministry of Science and Education of Republic of Croatia.
The publication fee is 1500 Eur. Subscription rate per volume (containing 4 issues) including surface postage is 100 Eur (from Vol. 55). Each issue costs 25 Eur. Payments should be made to the order of the Croatian Pharmaceutical Society, Masarykova 2, HR-10000 Zagreb, Croatia, through ZAGREBACKA BANKA d.d., Trg bana Josipa Jelačića 10, Zagreb, Croatia, account no. HR8923600001101367614 SWIFT ZABA HR 2X.
All submitted manuscripts should conform to generally accepted usage in composition of research papers. For technical requirements author should consult Instructions to authors and the recent issues.
AP is indexed in numerous world top international bibliographic bases, like Clarivate™ Web of Science Core Collection (SCI-Expanded, JCR/Science Edition, etc.), EMBASE/Excerpta Medica, MEDLINE/PubMed, Scopus/SCImago, and others. It is a Q2 journal (pharmaceutical sciences) according to SCImago and Clarivate™ JCI.